ArticleOrphanet journal of rare diseases2017
Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center.
Article in Orphanet journal of rare diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 citations in OpenAlex.
- Etiologies of intermediate uveitis in a tertiary center: an age-oriented medical assessment?Journal of ophthalmic inflammation and infection · 2025Article
- Combined pathological, microbiological and virological evaluation of vitreous aspirates: a retrospective evaluation of 374 vitrectomy specimens with non-neoplastic disorders.Eye (London, England) · 2025Article
- Neuromyelitis Optica-Associated Acute Intermediate Uveitis.International medical case reports journal · 2025Article
- The brain-eye connection: More than just action potentials.The Journal of experimental medicine · 2024Article
- [Uveitis and multiple sclerosis : Clinical aspects, diagnostics, management and treatment].Die Ophthalmologie · 2024Review
- Clinical characteristics of intermediate uveitis in adults according to criteria of the SUN working group.International ophthalmology · 2023Article
- Autoimmune Inflammatory Eye Disease: Demystifying Clinical Presentations for the Internist.Current allergy and asthma reports · 2023Review
- Sarcoidosis-Related Uveitis: A Review.Journal of clinical medicine · 2023Review
- Changes in Choroidal Vascularity Index (CVI) in Intermediate Uveitis.Translational vision science & technology · 2021Article
- Risk of Cataract in Intermediate Uveitis.American journal of ophthalmology · 2021Article
- Tick-borne encephalitis related uveitis: a case report.BMC ophthalmology · 2021Article
- Extrapulmonary sarcoidosis with a focus on cardiac, nervous system, and ocular involvement.EClinicalMedicine · 2021Review
- Uveitis as an Open Window to Systemic Inflammatory Diseases.Journal of clinical medicine · 2021Article
- Intermediate uveitis associated with MS: Diagnosis, clinical features, pathogenic mechanisms, and recommendations for management.Neurology(R) neuroimmunology & neuroinflammation · 2021Review
- [Guidelines nr. 24a intermediate uveitis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Intermediate Uveitis Etiology, Complications, Treatment, and Outcomes in a Colombian Uveitis Referral Center.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- The Relationship Between Vasoproliferative Tumor and Uveitis in a Multiple Sclerosis Patient: A Case Report and Review of the LiteratureTurkish journal of ophthalmology · 2019Review
- Inflammatory Ocular Diseases and Sphingolipid Signaling.Advances in experimental medicine and biology · 2019Review
- Bilateral Optic Atrophy and Epiretinal Membranes: An Atypical Presentation of Ocular Tuberculosis.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
- Intermediate uveitis: Etiologies and outcomes in a tertiary referral hospital in KSA.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with intermediate uveitis (IU) represent a heterogenous group characterized by a wide spectrum of etiologies and regional differences. Aim of the study was to analyze the characteristics of patients with IU examined in an academic center in Germany.
methodsWe conducted a retrospective analysis of the clinical records of all patients with intermediate uveitis referred to the Eye Center, University of Freiburg from 2007 to 2014. Diagnosis followed the Standardization in Uveitis Nomenclature (SUN) criteria. Data analysis included: etiology of IU, demographics, complications, treatment and visual acuity.
resultsWe identified 159 patients with intermediate uveitis during that period. Mean age at diagnosis was 35 years. Most are female (64%), and the mean duration of IU was 6.1 years (range 1 month - 35 years). Etiology of IU was idiopathic in 59%. Multiple sclerosis (MS) (20%) and sarcoidosis (10%) were frequent systemic causes of IU. Other etiologies including infectious diseases (tuberculosis, borreliosis) or immune-mediated conditions (eg, after vaccination) were present in 11%. The pattern of complications included macular edema (CME) (36%), cataract (24%), secondary glaucoma (7%), and epiretinal membrane formation (19%). Periphlebitis and optic neuritis were more frequent in conjunction with MS. Treatment comprised local and systemic steroids, immunosuppressive agents, biologics, and surgery. Best corrected visual acuity was better than 20/25 in 60% of the eyes after more than 10 years of follow-up.
conclusionsIn our German academic center, most IU cases were idiopathic or associated with MS or sarcoidosis. In contrast to other countries, infectious cases were rare. Patients' overall visual prognosis is favorable even when the duration of IU has been long and and despite numerous complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.